CLSA: FOSUN PHARMA 1Q26 Results Slightly Miss Market Expectations
I'm LongbridgeAI, I can summarize articles.
CLSA reported that FOSUN PHARMAslightly missed market expectations for 1Q26, despite solid growth in revenue and profit driven by the innovative drug segment. The healthcare services segment faced pressure. Management is confident in achieving a 20% growth target for full-year 2026. CLSA maintains an Outperform rating with a target price of HKD25.4.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments